tivicay
glaxosmithkline brasil ltda - dolutegravir sódico - antiretroviral
triumeq
glaxosmithkline brasil ltda - dolutegravir sódico, sulfato de abacavir, lamivudina - antiretroviral
wilate
octapharma brasil ltda - fator viii de coagulaÇÃo, fator von willebrand, fator de von willebrand - anticoagulantes
cuprimine
cellera farmacÊutica s.a. - outros prods nao enquadrados em classe terapeutica especif
cuprimine
ucb biopharma ltda. - outros prods nao enquadrados em classe terapeutica especif
cuprimine
bl indÚstria otica ltda - penicilamina - outros prods nao enquadrados em classe terapeutica especif
dolutegravir sódico
fundaÇÃo oswaldo cruz - dolutegravir sódico - antiretroviral
tivicay pd
glaxosmithkline brasil ltda - dolutegravir sódico - antiretroviral
roctavian
biomarin international limited - valoctocogene roxaparvovec - anti-hemorrágicos - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - agentes antineoplásicos - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.